Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 156 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Primary Open - Angle Glaucoma (POAG) Clear all

Conditions: Glaucoma, Primary Open Angle
Interventions: ELIOS Procedure; Device
Lead sponsor: Elios Vision, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 20
States / cities: Glendale, Arizona • Petaluma, California • Fort Collins, Colorado + 16 more

Conditions: Glaucoma and Ocular Hypertension
Interventions: ENV515-3 Travoprost XR, ENV515-1 Travoprost XR, ENV515-3-2 Travoprost XR; Drug
Lead sponsor: Envisia Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 14
States / cities: Chandler, Arizona • Garden Grove, California • Inglewood, California + 11 more

Conditions: Primary Open Angle Glaucoma, Low Tension Glaucoma, Cataract, Ocular Hypertension
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Open Angle Glaucoma (OAG)
Interventions: DSLT enables newly diagnosed patients to remain well controlled and off medications; Device
Lead sponsor: Barnet Dulaney Perkins Eye Centers; Network
Eligibility: 30 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Mesa, Arizona

Conditions: Glaucoma, Primary Open Angle Glaucoma, Glaucoma, Suspect
Interventions: Collection of genetic material; Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: 40 Years to 90 Years
Enrollment: 1,152 participants
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Primary Open Angle Glaucoma
Interventions: Hydrus Microstent, Cataract surgery, Monofocal IOL; Device · Procedure
Lead sponsor: Alcon Research; Industry
Eligibility: 45 Years and older
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 22
States / cities: Irvine, California • Sacramento, California • Loveland, Colorado + 19 more

Conditions: Glaucoma
Interventions: POLAT-001, Latanoprost ophthalmic solution; Drug
Lead sponsor: Peregrine Ophthalmic; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Goose Creek, South Carolina

Conditions: Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma, Chronic Angle Closure Glaucoma
Interventions: Not listed
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: T-2345, Xalatan; Drug
Lead sponsor: Nephron Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: Agency for Healthcare Research and Quality (AHRQ); Federal
Eligibility: 18 Years and older
Enrollment: 2,597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma; Drugs, Normal Tension Glaucoma, Primary Open-angle Glaucoma
Interventions: Timolol Maleate, Brimonidine Tartrate; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years to 90 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: Brimonidine purite 0.15%, Dorzolamide 2%, Brinzolamide 1%; Drug
Lead sponsor: Northwestern Ophthalmic Institute S.C.; Other
Eligibility: 41 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Glenview, Illinois

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: DE-104 ophthalmic solution, low concentration, DE-104 ophthalmic solution, medium concentration, DE-104 ophthalmic solution, high concentration, Placebo, 0.005% latanoprost; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 14
States / cities: Artesia, California • Los Angeles, California • Torrance, California + 9 more

Conditions: Primary Open Angle Glaucoma
Interventions: Hydrus Aqueous Implant, Cataract surgery; Device · Procedure
Lead sponsor: Ivantis, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 1,143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 26
States / cities: Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 23 more

Conditions: Primary Open Angle Glaucoma, Healthy Subjects
Interventions: SENSIMED Triggerfish; Device
Lead sponsor: Sensimed AG; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions: Latanoprost, Arm 2, Latanoprost SR insert; Drug
Lead sponsor: Daniel Moore; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: DE-104 medium concentration, DE-104 high concentration, Placebo, 0.005% latanoprost; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Artesia, California • Pasadena, California • San Francisco, California + 3 more

Conditions: Primary Open Angle Glaucoma, Open Angle Glaucoma
Interventions: Minimally Invasive Micro Sclerostomy Device; Device
Lead sponsor: Sanoculis Ltd; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Primary Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 1,540 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2022
U.S. locations: 3
States / cities: Birmingham, Alabama • La Jolla, California • New York, New York

Conditions: Exfoliation Syndrome, Primary Open Angle Glaucoma, Cataracts
Interventions: anterior segment OCT; Device
Lead sponsor: Duke University; Other
Eligibility: 40 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Ocular Hypertension, Primary Open Angle Glaucoma
Interventions: Nanodropper, Regular dropper; Device
Lead sponsor: 59th Medical Wing; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Lackland Air Force Base, Texas

Conditions: Primary Open-angle Glaucoma (POAG) Patient
Interventions: SENSIMED Triggerfish®; Device
Lead sponsor: Sensimed AG; Industry
Eligibility: 40 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Interventions: SHP639 (n=60), Placebo Comparator (n=24); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lexington, Massachusetts

Conditions: Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions: EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month), Vehicle Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

Excimer Laser Trabeculostomy Glaucoma Treatment Study

Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma

Assessing Ocular Hemodynamic Response to Surgical Intervention in Glaucoma

DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma

Development and Validation of a Model to Predict Fast Progression in Glaucoma

Hydrus® Microstent New Enrollment Post-Approval Study

POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma

Advanced Glaucoma Progression Study

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Comparative Effectiveness of Treatment Strategies for Primary Open-Angle Glaucoma

Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study

Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)

Efficacy of 24-hour Intraocular Pressure Fluctuation Recording With the SENSIMED Triggerfish Contact Lens Sensor

Safety Study of Latanoprost Slow Release Insert

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy

African Descent and Glaucoma Evaluation Study

Imaging Lens Deposits in Exfoliation Syndrome

Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial

Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients

Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

Topical Insulin for Glaucoma (TING2)